Last reviewed · How we verify

NCT05904509

Insulin Resistance in Atopic Dermatitis Patients

Completed Last updated 13 February 2024
What this trial tests

trial in Atopic Dermatitis in 32 participants. Completed in 1 October 2023.

Timeline
1 September 2022
Primary endpoint
1 October 2023
1 October 2023

Quick facts

Lead sponsorBezmialem Vakif University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment32
Start date1 September 2022
Primary completion1 October 2023
Estimated completion1 October 2023
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Bezmialem Vakif University

Who can join

Adults 2 to 80, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

Other Bezmialem Vakif University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05904509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing